Tanaka Fumiko, Kawakami Atsushi, Iwanaga Nozomi, Tamai Mami, Izumi Yasumori, Aratake Kouichiro, Arima Kazuhiko, Kamachi Makoto, Nakamura Hideki, Huang Mingguo, Ida Hiroaki, Origuchi Tomoki, Eguchi Katsumi
First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto.
Intern Med. 2006;45(5):313-6. doi: 10.2169/internalmedicine.45.1377. Epub 2006 Apr 3.
We have experienced a Takayasu arteritis (TA) patient, successfully treated with infliximab, who did not respond well to conventional therapy with glucocosteroid and methotrexate. Takayasu arteritis had developed in a 24-year-old woman (March 2003) who had been treated with glucocorticoid including methylprednisolone pulse therapy and methotrexate; however, she relapsed during the tapering of the dosage of oral prednisolone. Nineteen months after the first administration of glucocorticoid, 3 mg/kg of infliximab was introduced to the patient. The therapeutic efficacy of infliximab was markedly demonstrated; the patient's C-reactive protein (CRP) value returned to almost normal range with subsequent tapering of the dosage of oral prednisolone in the absence of further relapse. This is the first case presentation of TA in Japan successfully treated with infliximab.
我们有一位大动脉炎(TA)患者,对糖皮质激素和甲氨蝶呤的传统治疗反应不佳,但使用英夫利昔单抗治疗成功。一名24岁女性(2003年3月)患大动脉炎,曾接受包括甲泼尼龙冲击疗法和甲氨蝶呤在内的糖皮质激素治疗;然而,在口服泼尼松龙剂量逐渐减小时病情复发。首次使用糖皮质激素19个月后,给该患者使用3 mg/kg的英夫利昔单抗。英夫利昔单抗的治疗效果显著;患者的C反应蛋白(CRP)值恢复到几乎正常范围,随后口服泼尼松龙剂量逐渐减小,且未进一步复发。这是日本首例使用英夫利昔单抗成功治疗大动脉炎的病例报告。